Celldex Therapeutics, Inc.

Celldex Therapeutics to Participate on Therapeutic Workshop Panel at the BIO CEO & Investor Conference

10 Biotech Stocks With 100% Upside In 2012: Part One

Celldex Therapeutics to Participate on Therapeutic Workshop Panel at the BIO CEO & Investor Conference

Biotech Stocks To Watch In 2012

Celldex management to meet with Jefferies

Celldex shares should be bought at current levels, says Roth Capital

Jefferies Raises Price Target On Celldex Therapeutics (CLDX) 50%

Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger

Celldex to host research and development day

Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline

Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301

Celldex Therapeutics (CLDX) Begins Phase 1 Clinical Trial of CDX-301

Celldex initiates Phase 1 trial of CDX-301

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301

Healthcare Investment Conference Roudup

Healthcare investment conferences buzzing with chatter and activity

More Biotech Lessons Learned From JPM 2012

Celldex Therapeutics: A Potential Triple With Data On The Way

Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations

Celldex (CLDX) Commences Rindopepimut w/ Avastin Phase 2

Celldex initiates phase 2 study of Rindopepimut

Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations

Biotech Stock Mailbag: Most Important Events for 2012

Celldex Completes Accrual of CDX-011 Phase 2b “EMERGE” Study in Advanced Breast Cancer

Celldex completes accrual of EMERGE study

Celldex Completes Accrual of CDX-011 Phase 2b “EMERGE” Study in Advanced Breast Cancer

Celldex Therapeutics Presents Novel Preclinical Data on CDX-1127 at the American Society of Hematology Meeting in San Diego

Celldex presents preclinical data on CDX-1127

Celldex Therapeutics Presents Novel Preclinical Data on CDX-1127 at the American Society of Hematology Meeting in San Diego

Celldex Initiates ACT IV, A Pivotal International Phase 3 Trial Of Rindopepimut In Patients With Glioblastoma

Celldex, MDhHealth enter into agreement for MGMT Epigenetic test

CellDex to Use MDxHealthâs Assay in Phase III Brain Cancer Study

Jefferies Starts Celldex Therapeutics (CLDX) at Buy

Celldex initiated with a Buy at Jefferies

MDxHealth Enters Agreement with Celldex for Use of MGMT Epigenetic Test in Phase III Rindopepimut Study in Brain Cancer

Brain Cancer Vaccine Shows Positive Results

Celldex's Brain Cancer Vaccine Rindopepimut Shows Positive Results

Celldex (CLDX) Reports Publication of Rindopepimut Phase 2 Data

Celldex reports mature OS data for ACT III